Consensus Pfizer, Inc. Deutsche Boerse AG

Equities

PFE

US7170811035

Market Closed - Deutsche Boerse AG Other stock markets 19:48:29 17/05/2024 BST			5-day change	1st Jan Change
26.3 ^EUR	-1.22%		+0.79%	+0.75%

05-17	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE
05-17	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

Evolution of the average Target Price on Pfizer, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0affb70b705c0cf5.77aj6R_YguHGqQsNcMWGnPrO72BeWf06ocUbbf6xSzY.lvPr2EiQ0tiny2dHBKbtw7efhQgBDKxSkPUvOLnCCgaA4vW8WIixp6nmeA~2763d19cc253a6bb8b640f4ad4cfe052

Analyst Recommendations on Pfizer, Inc.

Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	05-17	MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating	05-13	MT
PFIZER INC : Buy rating from DZ Bank	05-02	ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28	05-02	MT
Leerink Adjusts Price Target on Pfizer to $29 From $27	05-02	MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating	05-02	MT
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating	05-02	MT
PFIZER INC : Jefferies gives a Buy rating	05-01	ZD
PFIZER INC : UBS remains Neutral	05-01	ZD
PFIZER INC : JP Morgan remains Neutral	05-01	ZD
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	04-17	MT
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	04-15	MT
PFIZER INC : JP Morgan remains Neutral	04-12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	04-12	MT
PFIZER INC : Berenberg remains Neutral	04-10	ZD
Argus Downgrades Pfizer to Hold From Buy	03-22	MT
PFIZER INC : JP Morgan sticks Neutral	03-07	ZD
PFIZER INC : JP Morgan sticks Neutral	03-01	ZD
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36	02-23	MT
China move leaves markets unfazed	02-20
Indian shares set to open higher ahead of national budget	02-01	RE
UBS Trims Pfizer Price Target to $28 From $29, Maintains Neutral Rating	01-31	MT
PFIZER INC : UBS gives a Neutral rating	01-31	ZD
PFIZER INC : Buy rating from Jefferies	01-30	ZD
PFIZER INC : DZ Bank maintains a Buy rating	01-30	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.64 USD

Average target price

31.94 USD

Spread / Average Target

+11.52%

High Price Target

45 USD

Spread / Highest target

+57.12%

Low Price Target

27 USD

Spread / Lowest Target

-5.73%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pfizer, Inc.

Redburn Atlantic
Morgan Stanley
Leerink Partners
BMO Capital
DZ BANK	Elmar Kraus
JPMORGAN	Chris Schott
UBS	Trung Huynh
JEFFERIES	Akash Tewari
BERENBERG	Kerry Holford
Argus
Guggenheim
TD Cowen
Cantor Fitzgerald
Truist Securities
Daiwa Securities
Wells Fargo Securities
Redburn
JPMorgan Chase
Barclays
Jefferies & Co.
Credit Suisse
SVB Securities LLC
Goldman Sachs
HSBC
Berenberg Bank
BofA Securities
Atlantic Equities
Citigroup
Mizuho Securities
Atlantic Securities
SVB Leerink
Independent Research
RBC
RBC Capital Markets
J.P. Morgan Chase

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar